Cardlytics (CDLX) Tops Q4 EPS by 47c; offers guidance

Cardlytics (NASDAQ: CDLX) reported Q4 EPS of $0.14, $0.47 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $89.2 million versus the consensus estimate of $84.7 million.

GUIDANCE:

Cardlytics sees Q1 2024 revenue of $70-73 million, versus the consensus of $66.46 million.

For earnings history and earnings-related data on Cardlytics (CDLX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c